Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Invest Ophthalmol Vis Sci. 2012 Aug 13;53(9):5520-6. doi: 10.1167/iovs.12-10010.
To test the hypothesis that autoantibodies against retinal pericytes could develop in diabetic retinopathy, and that these autoantibodies could induce retinal pericyte dysfunction/death via complement.
Human primary retinal pericytes cultured in media containing normal (5 mM) or high (30 mM) glucose concentrations were incubated with normal human sera in the presence of a retinal pericyte-reactive antibody, then their viability was assessed by a BCECF-based cytotoxicity assay, and their function was assessed by a T-cell proliferation assay. The pericytes were also analyzed by RT-PCR and flow cytometry to detect CD38, an established diabetes-associated cell surface autoantigen. The potential of the anti-CD38 antibodies in inducing pericyte cellular injury was evaluated using the same cytotoxicity assays. In addition, autoantibody-mediated cytotoxicity in mouse retinal pericytes sensitized by sera from mice with developing diabetic retinopathy or control normal mice were also studied.
Retinal pericyte-reactive antibodies induced cellular damage by activating complement in the serum. The antibody-injured pericytes had reduced efficacy in inhibiting T cells. Hyperglycemic culture conditions rendered pericytes more susceptible to antibody-mediated attack. CD38 was expressed in retinal pericytes, and upregulated by TNF-α and IFN-γ, and anti-CD38 antibodies induced pericyte cytotoxicity. Retinal pericytes sensitized with sera from chronic diabetic mice suffered significantly augmented cytotoxicity compared with those sensitized with sera from the control mice.
The autoantibody-initiated complement activation could be a mechanism underlying the loss of function, and eventually, death of retinal pericytes in diabetic patients, suggesting that inhibiting complement activation could be a novel therapeutic approach.
验证这样一个假说,即在糖尿病性视网膜病变中可能会产生针对视网膜周细胞的自身抗体,并且这些自身抗体可以通过补体诱导视网膜周细胞功能障碍/死亡。
将在含有正常(5mM)或高(30mM)葡萄糖浓度的培养基中培养的人原代视网膜周细胞与正常人血清在视网膜周细胞反应性抗体存在的情况下孵育,然后通过 BCECF 基于细胞毒性测定法评估其存活率,并通过 T 细胞增殖测定法评估其功能。通过 RT-PCR 和流式细胞术分析 CD38,这是一种已建立的与糖尿病相关的细胞表面自身抗原,以检测周细胞。使用相同的细胞毒性测定法评估抗 CD38 抗体在诱导周细胞细胞损伤中的潜力。此外,还研究了用来自发生糖尿病性视网膜病变的小鼠或对照正常小鼠的血清敏化的小鼠视网膜周细胞的自身抗体介导的细胞毒性。
血清中的补体激活了视网膜周细胞反应性抗体,从而诱导细胞损伤。抗体损伤的周细胞抑制 T 细胞的效果降低。高血糖培养条件使周细胞更容易受到抗体介导的攻击。CD38 在视网膜周细胞中表达,并受 TNF-α和 IFN-γ上调,抗 CD38 抗体诱导周细胞细胞毒性。与用对照小鼠的血清敏化的周细胞相比,用来自慢性糖尿病小鼠的血清敏化的周细胞遭受明显增强的细胞毒性。
自身抗体引发的补体激活可能是糖尿病患者视网膜周细胞功能丧失,最终死亡的机制,表明抑制补体激活可能是一种新的治疗方法。